企業プロフィール
CervoMed 株価・ニュース・カタリスト
- ティッカー:
- CRVO
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
2.62 USD (+2.34%)
終値
最終更新: 2026年8月21日
27.8M USD
時価総額
株価変動の要因
As of Aug 21, 2026, CRVO closed up 2.34% at $2.62. No new same-company headline was identified in the current news window.
企業概要
Neuroinflammation and Synaptic Dysfunction
CervoMed develops treatments for age-related brain disorders by targeting mechanisms that impair neuronal signaling. Its lead candidate focuses on p38 alpha MAP kinase, a driver of neuroinflammation and synaptic dysfunction.
Neflamapimod
Neflamapimod is an oral, brain-penetrant small molecule that selectively inhibits p38 alpha. It is intended to restore synaptic function and improve neuronal health in disorders affecting cholinergic brain networks.
Dementia With Lewy Bodies
The Phase 2b RewinD-LB study generated supportive results in dementia with Lewy bodies. CervoMed has selected the Phase 3 formulation and dose and aligned with U.S. and other regulators on a global, approximately 300-patient confirmatory trial.
Additional Neurologic Indications
Phase 2a studies evaluate neflamapimod in recovery after ischemic stroke and non-fluent-variant primary progressive aphasia. The molecule has also been selected for the EXPERTS-ALS platform trial.
今後のカタリスト
- Initiation of the Phase 3 dementia-with-Lewy-bodies trial expected in the second half of 2026, subject to financing.
- Topline Phase 2a ischemic-stroke-recovery data expected in the second half of 2026.
- Initial topline Phase 2a primary-progressive-aphasia data expected in the second half of 2026.
- Initiation of the EXPERTS-ALS trial expected in the second half of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。